<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-VI2YOKS2/8c1b7d13-2099-45e0-8cf9-569c93ecc93c/HTML"><dcterms:extent>40 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-VI2YOKS2/578628a7-82bf-4723-b312-e5c42b3f9afe/PDF"><dcterms:extent>98 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-VI2YOKS2/d9bd0a2c-6ee5-4c54-a865-36b42069a96e/TEXT"><dcterms:extent>39 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1992-2025"><edm:begin xml:lang="en">1992</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-VI2YOKS2"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S" /><dcterms:issued>2002</dcterms:issued><dc:creator>Jezeršek Novaković, Barbara</dc:creator><dc:creator>Novaković, Srdjan</dc:creator><dc:format xml:lang="sl">številka:1</dc:format><dc:format xml:lang="sl">10 strani</dc:format><dc:format xml:lang="sl">letnik:36</dc:format><dc:format xml:lang="sl">str. 53-62</dc:format><dc:identifier>ISSN:1318-2099</dc:identifier><dc:identifier>COBISSID:14748377</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-VI2YOKS2</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Association of Radiology and Oncology</dc:publisher><dcterms:isPartOf xml:lang="sl">Radiology and oncology (Ljubljana)</dcterms:isPartOf><dc:subject xml:lang="en">Cancer vaccines</dc:subject><dc:subject xml:lang="sl">cepljenje</dc:subject><dc:subject xml:lang="en">Gene therapy</dc:subject><dc:subject xml:lang="sl">Genska terapija</dc:subject><dc:subject xml:lang="en">Neoplasms</dc:subject><dc:subject xml:lang="sl">Novotvorbe</dc:subject><dc:subject xml:lang="sl">Novotvorbe, cepiva</dc:subject><dc:subject xml:lang="sl">rak (medicina)</dc:subject><dc:subject xml:lang="en">therapy</dc:subject><dc:subject xml:lang="en">tumor</dc:subject><dc:subject xml:lang="sl">vakcinacija</dc:subject><dc:subject xml:lang="sl">zdravljenje</dc:subject><dcterms:temporal rdf:resource="1992-2025" /><dc:title xml:lang="sl">A brief overview of the tumor vaccines through the last decade|</dc:title><dc:description xml:lang="sl">How to destroy cancer cells without damaging the normal cells? How to make conventional methods of systemic cancer treatment that predominantly comprise cytotoxic drugs more selective and prevent the development of drug resistance?There is an abundance of such guestions that do not have simple answers. If, a few years ago, unselective cytotoxic drugs were the method of choice for the treatment of cancer, in the last 25 years we are witnessing therapid transition of immunotherapy from the laboratories to the clinics. Among the most attractive and promising immunotherapies for cancer, a special place is reserved for tumor vaccines. Exploiting the latest knowledge in immunology, tumor physiology, as well as in molecular biology, many outstanding approaches for the creation of tumor vaccines have been developed.With no intention to be comprehensive, in the present article some of those approaches are reviewed</dc:description><dc:description xml:lang="sl">Kako bi lahko uničili tumorske celice, ne da bi ob tem prizadeli tudi normalnecelice v organizmu? Kako bi lahko spremenili sedanje pristope sistemskega zdravljenja, ki temelji predvsem na uporabi citostatikov, da bi le-to delovalo samo na tumorske celice in ne bi prišlo do pojava neobčutljivihceličnih klonov? Takšnih in podobnih vprašanj je pri zdravljenju raka veliko in predstavljajo osnovo za nove predklinične in klinične raziskaves skupnim ciljem odkriti učinkovito zdravilo ali način zdravljenja rakastih bolezni. Čeprav so še pred nekaj leti nesporno prevladovali citostatiki kot najučinkovitejše orožje v boju proti raku, se v zadnjih 25 letih na tem področju vse bolj uveljavlja biološka terapija. Posebej obetavna med biološkimi terapijami je priprava in uporaba tumorskih vakcin. Na osnovi novejših spoznanj s področij imunologije, tumorske fiziologije in molekularne biologije so raziskovalci oblikovali različne nadvse zanimive pristope k oblikovanju tumorskih vakcin. Pričujoči članek predstavlja kratek pregled nekaterih od navedenih pristopov</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-VI2YOKS2"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-VI2YOKS2" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-VI2YOKS2/578628a7-82bf-4723-b312-e5c42b3f9afe/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Društvo radiologije in onkologije</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-VI2YOKS2/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-VI2YOKS2" /></ore:Aggregation></rdf:RDF>